Shares of Haleon PLC Sponsored ADR (NYSE:HLN – Get Free Report) have been given a consensus rating of “Hold” by the eleven research firms that are currently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating, three have given a buy rating and two have given a strong buy rating to the company.
A number of equities research analysts have recently issued reports on the stock. Rothschild & Co Redburn cut shares of Haleon from a “strong-buy” rating to a “hold” rating in a report on Tuesday, June 16th. Wall Street Zen raised Haleon from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Zacks Research downgraded Haleon from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 21st. Royal Bank Of Canada restated a “sector perform” rating on shares of Haleon in a research note on Tuesday. Finally, Morgan Stanley reaffirmed an “overweight” rating on shares of Haleon in a research report on Thursday, August 6th.
Get Our Latest Stock Report on HLN
Haleon Stock Performance
Haleon Cuts Dividend
The firm also recently declared a dividend, which will be paid on Thursday, September 17th. Investors of record on Friday, August 14th will be paid a $0.0642 dividend. This represents a yield of 132.0%. The ex-dividend date is Friday, August 14th. Haleon’s dividend payout ratio is 64.10%.
Institutional Investors Weigh In On Haleon
Several hedge funds have recently added to or reduced their stakes in HLN. Wallace Capital Management Inc. acquired a new position in shares of Haleon in the second quarter valued at $110,000. Fiduciary Financial Group LLC acquired a new stake in shares of Haleon during the 2nd quarter worth about $97,000. GAMMA Investing LLC boosted its holdings in shares of Haleon by 18.1% during the 2nd quarter. GAMMA Investing LLC now owns 34,810 shares of the company’s stock worth $325,000 after buying an additional 5,338 shares during the period. Arlington Partners LLC grew its stake in Haleon by 23.0% in the 2nd quarter. Arlington Partners LLC now owns 29,826 shares of the company’s stock valued at $278,000 after buying an additional 5,580 shares during the last quarter. Finally, Pacific Excel Wealth Advisors Inc. acquired a new position in Haleon in the 2nd quarter valued at about $209,000. Institutional investors and hedge funds own 6.67% of the company’s stock.
Haleon Company Profile
Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.
The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.
Read More
- Five stocks we like better than Haleon
- Is Best Buy the AI Winner Hiding in the Electronics Aisle?
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
- Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
- Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.
